Status:
UNKNOWN
Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT
Lead Sponsor:
National Research Center for Hematology, Russia
Conditions:
Mesenchymal Stem Cell Transplantation
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Multipotent mesenchymal stromal cells (MSCs) participate in the formation of bone marrow niches for hematopoietic stem cells. Donor MSCs can serve as a source of recovery for niches in patients with g...
Eligibility Criteria
Inclusion
- All patients with primary graft failure after allo-HSCT
- Available MSC for this patient
Exclusion
- N/A
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03389919
Start Date
January 1 2017
End Date
December 31 2022
Last Update
January 4 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
BMT department
Moscow, Russia